Clinical trial · Expanded Access
Expanded Access to Telisotuzumab Vedotin
NCT04830202CI-TRIAL-00111303temporarily not availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Telisotuzumab vedotin prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer (NSCLC) | Lung Non-Small Cell Carcinoma | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Telisotuzumab vedotin | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Minimum age
- 18 Years
Show eligibility criteria text
Exclusion Criteria: * There are other suitable treatment options. * The participant qualifies for ongoing clinical trials.
References
Publications (0)
Data not yet available
No reference posted for this study.